About Intellia Therapeutics, Inc.
https://www.intelliatx.comIntellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.
CEO
John M. Leonard
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
Chardan Capital
Buy
B of A Securities
Buy
Guggenheim
Buy
Canaccord Genuity
Buy
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
ARK INVESTMENT MANAGEMENT LLC
Shares:11.92M
Value:$143.27M
VANGUARD GROUP INC
Shares:11.04M
Value:$132.76M
BLACKROCK INC.
Shares:9.6M
Value:$115.36M
Summary
Showing Top 3 of 362
About Intellia Therapeutics, Inc.
https://www.intelliatx.comIntellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $13.78M ▼ | $46.31M ▼ | $-101.32M ▼ | -735.19% ▼ | $-0.92 ▲ | $-96.39M ▲ |
| Q2-2025 | $14.24M ▼ | $124.24M ▼ | $-101.25M ▲ | -710.81% ▼ | $-0.98 ▲ | $-107.52M ▲ |
| Q1-2025 | $16.63M ▲ | $137.43M ▼ | $-114.33M ▲ | -687.61% ▲ | $-1.1 ▲ | $-118.31M ▲ |
| Q4-2024 | $12.87M ▲ | $149.32M ▼ | $-128.9M ▲ | -1K% ▲ | $-1.27 ▲ | $-133.88M ▲ |
| Q3-2024 | $9.11M | $153.88M | $-135.71M | -1.49K% | $-1.34 | $-142.16M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $511.04M ▲ | $925.27M ▲ | $176.85M ▼ | $748.42M ▲ |
| Q2-2025 | $459.65M ▼ | $898.89M ▼ | $183.64M ▼ | $715.25M ▼ |
| Q1-2025 | $503.75M ▼ | $986.16M ▼ | $206.24M ▼ | $779.92M ▼ |
| Q4-2024 | $601.51M ▼ | $1.19B ▲ | $319.06M ▲ | $871.96M ▼ |
| Q3-2024 | $658.11M | $1.17B | $210.74M | $962.62M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-101.32M ▼ | $-76.9M ▲ | $-741K ▼ | $114.86M ▲ | $37.22M ▲ | $-76.93M ▲ |
| Q2-2025 | $-101.25M ▲ | $-99.62M ▲ | $106.91M ▲ | $14.65M ▲ | $21.94M ▲ | $-99.86M ▲ |
| Q1-2025 | $-114.33M ▲ | $-148.93M ▼ | $94.33M ▼ | $0 ▼ | $-54.6M ▼ | $-149.66M ▼ |
| Q4-2024 | $-128.9M ▲ | $-85.19M ▼ | $151.56M ▲ | $2.32M ▼ | $68.69M ▲ | $-86.18M ▼ |
| Q3-2024 | $-135.71M | $-84.84M | $-7.71M | $82.19M | $-10.35M | $-86.12M |
CEO
John M. Leonard
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 146
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Truist Securities
Buy
Chardan Capital
Buy
B of A Securities
Buy
Guggenheim
Buy
Canaccord Genuity
Buy
Grade Summary
Showing Top 6 of 19
Price Target
Institutional Ownership
ARK INVESTMENT MANAGEMENT LLC
Shares:11.92M
Value:$143.27M
VANGUARD GROUP INC
Shares:11.04M
Value:$132.76M
BLACKROCK INC.
Shares:9.6M
Value:$115.36M
Summary
Showing Top 3 of 362